- Home
- PHAT vs PTA Comparison
PHAT vs PTA Comparison
Compare PHAT & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | PTA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.6M | 1.1B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAT | PTA |
|---|---|---|
| Price | $13.92 | $19.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.33 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 159.2K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $147,190,000.00 | N/A |
| Revenue This Year | $220.82 | N/A |
| Revenue Next Year | $82.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 460.30 | N/A |
| 52 Week Low | $2.21 | $15.84 |
| 52 Week High | $18.31 | $19.67 |
Technical Indicators
Market Signals| Indicator | PHAT | PTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 51.49 |
| Support Level | $13.79 | $19.46 |
| Resistance Level | $16.12 | $19.75 |
| Average True Range (ATR) | 0.95 | 0.14 |
| MACD | -0.33 | 0.03 |
| Stochastic Oscillator | 5.72 | 64.62 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.